MENG Qing-wen, LU Li-gong. Phase Ⅲ Study of Sorafenib after Transarterial Chemoembolisation in Japanese and Korean Patients with Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2012, 12(2): 99-102. DOI: 10.3969/j.issn.1671-5144.2012.02.013
|
Citation:
|
MENG Qing-wen, LU Li-gong. Phase Ⅲ Study of Sorafenib after Transarterial Chemoembolisation in Japanese and Korean Patients with Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2012, 12(2): 99-102. DOI: 10.3969/j.issn.1671-5144.2012.02.013
|
MENG Qing-wen, LU Li-gong. Phase Ⅲ Study of Sorafenib after Transarterial Chemoembolisation in Japanese and Korean Patients with Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2012, 12(2): 99-102. DOI: 10.3969/j.issn.1671-5144.2012.02.013
|
Citation:
|
MENG Qing-wen, LU Li-gong. Phase Ⅲ Study of Sorafenib after Transarterial Chemoembolisation in Japanese and Korean Patients with Unresectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2012, 12(2): 99-102. DOI: 10.3969/j.issn.1671-5144.2012.02.013
|
DownLoad: